Antimicrobial drug developer HOOKIPA Pharma (NASDAQ:HOOK) announced Thursday that Gilead Sciences (NASDAQ:GILD) has agreed to acquire some of its assets for a total consideration of up to $10M.

Gilead purchased 15 million shares and holds 19.4% stake in HOOKIPA. Equity investment is to advance the Gilead-partnered HIV program through Phase 1 trial expected to start in 1H of 2024.

HB-400 (NCT05770895) is currently being evaluated in a Phase 1 trial and is one of two independent development programs in HOOKIPA’s collaboration and license agreement with Gilead Sciences ...

HB-400 is one of two novel compounds being developed in collaboration with Gilead. “Dosing of the first person in the Phase 1 clinical trial of HB-400 is an important milestone for HOOKIPA ...

The hepatitis B program is one of two independent development programs in HOOKIPA’s collaboration and license agreement with Gilead. The other program aims to develop a novel arenaviral vaccine ...

Gilead holds 19.4% of HOOKIPA’s outstanding shares of common stock Equity investment is to advance the Gilead-partnered HIV therapeutic program through Phase 1; trial expected to commence in the ...

Then Gilead on Thursday disclosed it bought 15 million shares of Austria-based HIV drug-development partner Hookipa Pharma Inc. (NASDAQ: HOOK) for $21.25 million, with Hookipa having an option to ...

Gilead is solely responsible for further development and commercialization of the hepatitis B product candidate. HOOKIPA is eligible to receive milestone payments based on the achievement of ...

Gilead is solely responsible for further development and commercialization of HB-400, referenced as GS-2829 and GS-6779. HOOKIPA earned a $5 million non-dilutive payment under its collaboration ...